Immune ‘Don’t Eat Me’ Blocker Plus Azacitidine Shows 72.7% Response Rate in Phase II CMML Trial
A phase II trial of 24 Chinese patients with higher-risk chronic myelomonocytic leukemia found that the SIRPĪ±-Fc fusion protein timdarpacept ...
Tag: IMM01
POPULAR NEWS
-
Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant
-
Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast
-
ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth
-
Systematic review maps sustainability tensions in offshore wind development